List view / Grid view
Sheraz Gul explores how machine learning and artificial intelligence represent an exciting opportunity for the drug discovery industry, with the potential to develop highly optimised small molecules.
The length of time between the administration of a COVID-19 vaccine and evidence of a robust immune response to Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) means that treatments are still required. In this article, Sheraz Gul and Alp Tegin Sahin explore the various therapeutic targets that have been identified…
Sheraz Gul reviews where we are a year into the COVID-19 pandemic and the treatment options currently available. He also highlights the potential opportunities and challenges posed by SARS-CoV-2 vaccines.
As the global COVID-19 situation is rapidly changing, staying abreast with the latest news can be challenging. In this article, Sheraz Gul provides an overview of the broad range of potential treatments in development and discusses how the regulatory landscape can shift at any time.
Although many potential targets have been identified for Alzheimer’s disease (AD), there is no effective treatment for this debilitating condition. In this article, Monika Schmidt and Sheraz Gul delve into the key proteins implicated in AD and suggest how phenotypic assays could aid in AD drug discovery.
Sheraz Gul explores current research developments to help treat and tackle the spread of COVID-19.
It is said that, on average, it takes a new drug 12 years to go from research lab to patient, with many thousands of candidates discarded along the way. Can artificial intelligence (AI) help to speed things up? Sheraz Gul and Alp Sahin provide an overview of an AI approach…
